PL369848A1 - Liofilizowany preparat zawierający przeciwciała przeciw receptorowi EGF - Google Patents

Liofilizowany preparat zawierający przeciwciała przeciw receptorowi EGF

Info

Publication number
PL369848A1
PL369848A1 PL02369848A PL36984802A PL369848A1 PL 369848 A1 PL369848 A1 PL 369848A1 PL 02369848 A PL02369848 A PL 02369848A PL 36984802 A PL36984802 A PL 36984802A PL 369848 A1 PL369848 A1 PL 369848A1
Authority
PL
Poland
Prior art keywords
preparation containing
egf receptor
lyophilized preparation
containing antibodies
antibodies
Prior art date
Application number
PL02369848A
Other languages
English (en)
Other versions
PL205982B1 (pl
Inventor
Hanns-Christian Mahler
Hans-Peter Zobel
Robert Müller
Christiane Bachmann
Udo Haas
Ludwig Krüger
Ulrike Martini-Marr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL369848A1 publication Critical patent/PL369848A1/pl
Publication of PL205982B1 publication Critical patent/PL205982B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL369848A 2001-12-21 2002-11-25 Liofilizowany preparat zawierający przeciwciała przeciw receptorowi EGF oraz sposób jego otrzymywania PL205982B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10163459A DE10163459A1 (de) 2001-12-21 2001-12-21 Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor

Publications (2)

Publication Number Publication Date
PL369848A1 true PL369848A1 (pl) 2005-05-02
PL205982B1 PL205982B1 (pl) 2010-06-30

Family

ID=7710502

Family Applications (1)

Application Number Title Priority Date Filing Date
PL369848A PL205982B1 (pl) 2001-12-21 2002-11-25 Liofilizowany preparat zawierający przeciwciała przeciw receptorowi EGF oraz sposób jego otrzymywania

Country Status (26)

Country Link
US (2) US20050220786A1 (pl)
EP (1) EP1455824B1 (pl)
JP (1) JP2005513110A (pl)
KR (1) KR100942399B1 (pl)
CN (1) CN100515495C (pl)
AR (1) AR037971A1 (pl)
AT (1) ATE403439T1 (pl)
AU (1) AU2002358533B2 (pl)
BR (1) BR0215266A (pl)
CA (1) CA2470316A1 (pl)
CO (1) CO5590939A2 (pl)
DE (2) DE10163459A1 (pl)
EC (1) ECSP045197A (pl)
ES (1) ES2309220T3 (pl)
HU (1) HUP0402192A2 (pl)
IL (1) IL162588A0 (pl)
MX (1) MXPA04006059A (pl)
MY (1) MY139055A (pl)
NZ (1) NZ534211A (pl)
PE (1) PE20030777A1 (pl)
PL (1) PL205982B1 (pl)
RU (1) RU2339402C2 (pl)
TW (1) TWI318884B (pl)
UA (1) UA83461C2 (pl)
WO (1) WO2003053465A2 (pl)
ZA (1) ZA200405785B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
CZ20014083A3 (cs) * 1999-05-14 2002-08-14 Imclone Systems Incorporated Léčivo pro indikaci růstu refrakterních nádorů
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
RU2390353C2 (ru) * 2004-02-12 2010-05-27 Мерк Патент Гмбх Высококонцентрированные жидкие композиции анти-egfr антител
CA2560305C (en) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
US8476239B2 (en) * 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
CA2654794A1 (en) * 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
TW200826974A (en) * 2006-09-07 2008-07-01 Kirin Pharma Kk Stable lyophilized pharmaceutical preparation comprising antibody
TW200831129A (en) * 2006-10-06 2008-08-01 Amgen Inc Stable formulations
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
CA2827052C (en) 2011-02-11 2022-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
PT2691112T (pt) * 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
AU2017386888B2 (en) 2016-12-28 2024-08-08 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
SG11202011538RA (en) * 2018-06-01 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugate compositions
JP7597450B2 (ja) 2018-10-19 2024-12-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸癌の治療のためのアビツズマブ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
KR100215027B1 (ko) * 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
KR20110008112A (ko) * 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법

Also Published As

Publication number Publication date
MXPA04006059A (es) 2004-09-27
PE20030777A1 (es) 2003-09-11
WO2003053465A2 (de) 2003-07-03
AR037971A1 (es) 2004-12-22
KR20040074099A (ko) 2004-08-21
TWI318884B (en) 2010-01-01
NZ534211A (en) 2006-01-27
ES2309220T3 (es) 2008-12-16
JP2005513110A (ja) 2005-05-12
RU2339402C2 (ru) 2008-11-27
EP1455824B1 (de) 2008-08-06
IL162588A0 (en) 2005-11-20
CO5590939A2 (es) 2005-12-30
PL205982B1 (pl) 2010-06-30
US20050220786A1 (en) 2005-10-06
DE10163459A1 (de) 2003-07-03
DE50212615D1 (de) 2008-09-18
ECSP045197A (es) 2004-08-27
US20080166346A1 (en) 2008-07-10
EP1455824A2 (de) 2004-09-15
KR100942399B1 (ko) 2010-02-17
TW200306205A (en) 2003-11-16
AU2002358533B2 (en) 2009-01-15
WO2003053465A3 (de) 2003-12-04
ZA200405785B (en) 2005-06-29
HUP0402192A2 (hu) 2005-01-28
HK1071306A1 (zh) 2005-07-15
UA83461C2 (uk) 2008-07-25
CA2470316A1 (en) 2003-07-03
MY139055A (en) 2009-08-28
CN1606455A (zh) 2005-04-13
CN100515495C (zh) 2009-07-22
ATE403439T1 (de) 2008-08-15
AU2002358533A1 (en) 2003-07-09
RU2004122632A (ru) 2005-05-20
BR0215266A (pt) 2004-12-07

Similar Documents

Publication Publication Date Title
IL162588A0 (en) Lyophilized preparation containing antibodies to the egf receptor
IL235116A0 (en) Antibodies to opgl (osteoprotegerin ligand)
EP1432444A4 (en) ANTI-BETA ANTIBODIES
PT1361893E (pt) Anticorpos anti-rfce modificados com imunogenicidade reduzida
HUP0402250A3 (en) Antibodies to vla-1
PL356297A1 (pl) Zrekombinowane przeciwciała na ludzką interleukinę-1 beta
GB9911569D0 (en) Antibodies
AU2002365649A8 (en) Anti-dota antibody
HUP0400030A3 (en) Antibodies specific for cd44v6
GB0115385D0 (en) Novel preparation
EP1455822A4 (en) LYOPHILIZED MONOCLONAL ANTIBODY COMPOSITIONS
GB0118009D0 (en) Novel preparation
GB2364057A8 (en) G protein coupled receptor
GB9915419D0 (en) Antigens
EP1354947A4 (en) NEW POLYPEPTIDE
GB0031284D0 (en) High affinity antibodies
GB0118696D0 (en) Novel antibodies
HRP20030931A2 (en) Antibodies specific for cd44v6
GB0119553D0 (en) Antibodies
GB0120494D0 (en) Novel antibody
GB0003527D0 (en) Antibodies
GB0005071D0 (en) Antibodies
GB0020568D0 (en) Novel antibody
GB0119479D0 (en) Antigens
GB0112448D0 (en) Antigens

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20101125